skip to main content

SciTech ConnectSciTech Connect

Title: Protection of non-human primates against rabies with an adenovirus recombinant vaccine

Rabies remains a major neglected global zoonosis. New vaccine strategies are needed for human rabies prophylaxis. A single intramuscular immunization with a moderate dose of an experimental chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein, resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model. Taken together, these data demonstrate the safety, immunogenicity, and efficacy of the recombinant Ad-rabies vector for further consideration in human clinical trials. - Highlights: • Pre-exposure vaccination with vaccine based on a chimpanzee derived adenovirus protects against rabies. • Protection is sustained. • Protection is achieved with single low-dose of vaccine given intramuscularly. • Protection is not affected by pre-existing antibodies to common human serotypes of adenovirus.
Authors:
 [1] ;  [2] ;  [1] ;  [3] ;  [4]
  1. The Wistar Institute of Anatomy and Biology, Philadelphia, PA (United States)
  2. Centers for Disease Control and Prevention, Atlanta, GA (United States)
  3. The Global Alliance for Rabies Control, Manhattan, KS (United States)
  4. (Saint Kitts and Nevis)
Publication Date:
OSTI Identifier:
22435016
Resource Type:
Journal Article
Resource Relation:
Journal Name: Virology; Journal Volume: 450-451; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ADENOVIRUS; ANTIBODIES; CLINICAL TRIALS; DOSES; GLYCOPROTEINS; HUMAN POPULATIONS; PREVENTIVE MEDICINE; PRIMATES; RABIES; SAFETY; VACCINES